Heart Failure Medications: What Each Drug Does and Why It Matters

If you or a loved one has been told “you have heart failure,” the medication list can feel overwhelming. Here is the logic behind it. Heart failure doesn’t mean the heart has stopped. It means the heart isn’t pumping or filling well enough to meet the body’s needs.

First, Know Your Type

Treatment depends on the ejection fraction (EF), measured on an echocardiogram.

TypeEF
HFrEF (reduced)≤ 40%
HFmrEF (mildly reduced)41 to 49%
HFpEF (preserved)≥ 50%

The strongest evidence for drugs that extend life is in HFrEF, so that’s where most of this post focuses.

The Four Pillars of HFrEF Therapy (GDMT)

Guideline-directed medical therapy (GDMT) combines four drug classes. Each one reduces hospitalizations and mortality, and they work best together.

1. ARNI, ACE inhibitor, or ARB (blocks the RAAS system)

  • Sacubitril/valsartan (Entresto) is preferred when tolerated. Alternatives are ACE inhibitors (lisinopril, enalapril) or ARBs (losartan, valsartan).
  • Watch for low blood pressure, high potassium, kidney changes, and cough (ACE inhibitors).
  • Never combine an ARNI with an ACE inhibitor. The risk is angioedema. Switching from an ACE inhibitor requires a 36-hour washout.

2. Evidence-based beta-blocker

  • Only three have proven benefit in HFrEF: carvedilol, metoprolol succinate, and bisoprolol.
  • Not all beta-blockers are equal. Metoprolol tartrate and atenolol are not the HF drugs.
  • Start low, go slow. Initiate in stable (euvolemic) patients, not during acute decompensation.
  • Common effects: fatigue, dizziness, slow heart rate.

3. Mineralocorticoid receptor antagonist (MRA)

  • Spironolactone or eplerenone.
  • Check potassium and creatinine at baseline, within about a week, and regularly after that.
  • Spironolactone can cause breast tenderness or enlargement. Eplerenone is an alternative.

4. SGLT2 inhibitor

  • Dapagliflozin (Farxiga) or empagliflozin (Jardiance).
  • Originally diabetes drugs, but they help heart failure patients with or without diabetes.
  • Watch for genital yeast infections and volume depletion. Rarely, ketoacidosis occurs (even with normal glucose). Hold during acute illness with poor oral intake or before surgery, per your clinician’s guidance.

Diuretics: For Symptoms, Not Survival

Loop diuretics (furosemide, bumetanide, torsemide) relieve congestion: swelling, shortness of breath, and fluid weight. They improve how patients feel, but they have not been shown to extend life. The goal is the lowest dose that keeps you dry.

Add-On and Special-Situation Drugs

  • Hydralazine + isosorbide dinitrate: for patients who can’t take ARNI/ACEi/ARB, or as an add-on in self-identified Black patients with NYHA class III to IV HFrEF.
  • Ivabradine: for patients in sinus rhythm with a resting heart rate ≥ 70 despite maximally tolerated beta-blocker.
  • Vericiguat: considered after a recent worsening heart failure event.
  • Digoxin: may reduce hospitalizations in selected patients, but needs careful dosing and level monitoring.

What About HFpEF and HFmrEF?

Options have expanded in recent years.

  • SGLT2 inhibitors are now a mainstay.
  • MRAs, ARNI, and ARBs may help in selected patients, especially with lower EF in the range.
  • Finerenone and GLP-1-based therapies (semaglutide, tirzepatide, in patients with obesity) have newer evidence. Ask your cardiologist whether they fit your situation.
  • Diuretics remain key for congestion, and treating blood pressure, atrial fibrillation, and other conditions matters a lot.

Medications to Be Careful With

Always check with your provider or pharmacist before taking:

  • NSAIDs (ibuprofen, naproxen): cause fluid retention and can worsen heart failure
  • Non-dihydropyridine calcium channel blockers (diltiazem, verapamil) in HFrEF
  • Thiazolidinediones (pioglitazone)
  • High-sodium or potassium-based salt substitutes, especially if you take an MRA, ACEi, ARB, or ARNI
  • Some herbal supplements and OTC cold medicines (decongestants)

Your Part in Treatment

  • Weigh yourself daily, same time, same scale. Call your provider if you gain 2 to 3 lb in a day or 5 lb in a week.
  • Limit sodium as your clinician advises.
  • Bring a full medication list to every visit, including supplements.
  • Don’t stop a heart failure medication on your own, even if you feel better. Feeling better often means the medications are working.
  • Know the warning signs: worsening breathlessness, swelling, needing more pillows to sleep, new dizziness or fainting.

Key Takeaways

  1. For HFrEF, four drug classes form the foundation: ARNI/ACEi/ARB, evidence-based beta-blocker, MRA, and SGLT2 inhibitor.
  2. Diuretics relieve symptoms, but the four pillars help you live longer and stay out of the hospital.
  3. Doses are usually titrated up gradually, and lab monitoring matters.
  4. Treatment is a partnership. Daily weights, a low-sodium diet, and follow-up make a real difference.

**This post is for general education and doesn’t replace individualized medical advice. Guidelines evolve, so always confirm with your healthcare provider.

References

American College of Cardiology, American Heart Association, & Heart Failure Society of America. (2022). 2022 AHA/ACC/HFSA guideline for the management of heart failure: A report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Journal of the American College of Cardiology, 79(17), e263–e421. https://doi.org/10.1016/j.jacc.2021.12.012

European Society of Cardiology. (2021). 2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure. European Heart Journal, 42(36), 3599–3726. https://doi.org/10.1093/eurheartj/ehab368

Maddox, T. M., Januzzi, J. L., Jr., Allen, L. A., Breathett, K., Butler, J., Davis, L. L., Fonarow, G. C., Ibrahim, N. E., Lindenfeld, J., Masoudi, F. A., Muzzarelli, S., & Peterson, P. N. (2024). 2024 ACC expert consensus decision pathway on clinical guidance for management of heart failure with reduced ejection fraction. Journal of the American College of Cardiology, 83(15), 1444–1488. https://doi.org/10.1016/j.jacc.2024.01.011